Dasatinib
SenolyticsPreclinicalAlso known as: Sprycel (brand name), BMS-354825, N-(2-Chloro-6-methylphenyl)-2-[[6-[4-(2-hydroxyethyl)-1-piperazinyl]-2-methyl-4-pyrimidinyl]amino]-5-thiazolecarboxamide, BCR-ABL inhibitor, Src family kinase inhibitor, D (in D+Q senolytic combination)
Dasatinib (SPRYCEL) is a second-generation oral tyrosine kinase inhibitor (TKI) with FDA approvals for chronic myeloid leukemia (CML) and Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL). It is also, critically for longevity medicine, the "D" component of the landmark D+Q (dasatinib + quercetin) senolytic drug combination first reported by Zhu, Tchkonia, and Kirkland in 2015 (PMID 25754370) — the first demonstrated pharmacologic strategy to selectively kill senescent cells ("zombie cells") while sparing healthy cells.
Overview
At A Glance
Dasatinib's mechanism of action spans multiple tyrosine kinases with different relevance to oncology versus senolytic applications. Primary kinase targets: Dasatinib is an ATP-competitive inhibitor with high-affinity binding to BCR-ABL fusion kinase, SRC family kinases (SRC, LCK,…
Mechanism of Action
Dasatinib's mechanism of action spans multiple tyrosine kinases with different relevance to oncology versus senolytic applications. Primary kinase targets: Dasatinib is an ATP-competitive inhibitor with high-affinity binding to BCR-ABL fusion kinase, SRC family kinases (SRC, LCK, YES, FYN, LYN, FGR, HCK, BLK), c-KIT (stem cell factor receptor), PDGFR-α and PDGFR-β, ephrin receptors (EphA2, EphB4, others), and multiple other tyrosine kinases at varying potency. IC50 values vary: BCR-ABL wild-type IC50 ~0.6 nM (compared to imatinib ~195 nM, hence the 325-fold potency improvement); SRC family kinases IC50 ~0.5 nM; c-KIT IC50 ~5 nM; PDGFRβ IC50 ~28 nM. This multi-kinase activity is dasatinib's defining feature — unlike imatinib (relatively selective for BCR-ABL), dasatinib inhibits a broad kinase panel, which underlies both its oncologic efficacy across additional tumor types and its senolytic activity. Oncologic Mechanism: For CML, dasatinib inhibits the constitutively active BCR-ABL kinase that arises from the Philadelphia chromosome translocation t(9;22). BCR-ABL phosphorylates multiple downstream substrates driving uncontrolled proliferation, survival, and leukemogenesis of myeloid precursors. Dasatinib's ATP-competitive inhibition blocks BCR-ABL autophosphorylation and substrate phosphorylation, restoring apoptotic competence and reducing proliferation in leukemic cells. Dasatinib retains activity against most imatinib-resistant BCR-ABL mutations (Y253H, E255K/V, F359V, H396R) except T315I. For Ph+ ALL, similar mechanism applies. For chronic exposure in oncologic contexts, the multi-kinase activity produces substantial on-target effects beyond BCR-ABL — SRC family kinases regulate many normal cellular processes; their inhibition contributes to the side effect profile. Senolytic Mechanism: The mechanism by which dasatinib selectively kills senescent cells was elucidated by Zhu et al 2015 (PMID 25754370) and subsequent work. Senescent cells paradoxically require activation of anti-apoptotic "pro-survival networks" (SCAPs — Senescent-Cell Anti-apoptotic Pathways) to resist apoptotic cell death despite their stressed, senescent state. These pro-survival networks include: (1) BCL-2 family members (BCL-XL, BCL-W, BCL-2) — inhibitors like navitoclax (ABT-263) exploit this; (2) PI3K/AKT/mTOR pathway survival signaling; (3) dependence receptor-induced survival signaling; (4) SRC kinase family activity; (5) ephrin-ephrin receptor signaling promoting survival; (6) p53/p21 modulation of apoptotic thresholds. Different senolytic drugs target different SCAPs. Dasatinib's key senolytic mechanism is inhibition of SRC kinase family signaling AND ephrin receptor signaling (EphB4, EphA2) in senescent cells. Different senescent cell types exhibit differential dependence on different SCAPs — dasatinib is particularly effective against senescent adipocyte progenitors, senescent human umbilical vein endothelial cells (HUVECs), and some other senescent cell types, while less active against senescent human preadipocytes or senescent fibroblasts. Quercetin (the Q in D+Q) inhibits different SCAP components — primarily the PI3K/AKT pathway, BCL-XL, and HIF-1α — with complementary specificity against senescent human endothelial cells, senescent mouse embryonic fibroblasts, and senescent pre-adipocytes. The synergy of D+Q arises because the combination targets a broader range of senescent cell types than either drug alone, achieving more complete senolysis. In mouse aging models (Zhu 2015, Xu 2018, Ogrodnik 2017, and many others), D+Q treatment: (1) reduces senescent cell burden across tissues (adipose, kidney, liver, brain, bone, cardiovascular); (2) reduces SASP factor expression (IL-6, IL-8, TNF-α, MMPs, chemokines); (3) extends healthspan measures (physical function, cognitive function, cardiovascular function); (4) extends median lifespan by ~36% when initiated at old age (Xu 2018); (5) attenuates specific age-related pathologies (senile frailty, osteoarthritis progression, hepatic steatosis, tendinopathy, aortic stiffness, adipose dysfunction); (6) reverses specific disease-related senescence burden (idiopathic pulmonary fibrosis, diabetic kidney disease, Alzheimer disease-associated senescence in mouse models). Pharmacokinetics: Oral dasatinib is rapidly absorbed with Tmax 0.5-6 hours (typically 1-2 hours). Bioavailability is moderate and substantially pH-dependent — gastric acid facilitates dissolution, and drugs that raise gastric pH (PPIs like omeprazole, H2 blockers like famotidine, antacids) dramatically reduce absorption. Dasatinib can be taken with or without food. Elimination half-life is 3-5 hours for the parent compound (relatively short — contributing to feasibility of intermittent dosing). Metabolism is primarily via CYP3A4 to multiple metabolites (including an active N-dealkylated metabolite). Elimination is predominantly fecal (>80%) with minimal renal excretion. CYP3A4 Interactions (Critical): Dasatinib is a CYP3A4 substrate. Strong CYP3A4 inhibitors (ketoconazole, itraconazole, clarithromycin, ritonavir, cobicistat, grapefruit juice regular consumption) dramatically increase dasatinib exposure — contraindicated combinations. Strong CYP3A4 inducers (rifampin, phenytoin, carbamazepine, St. John's Wort, enzalutamide) decrease dasatinib exposure — avoid combination. Moderate CYP3A4 inhibitors/inducers require dose adjustment. Gastric pH Interactions: PPIs (omeprazole, esomeprazole, pantoprazole, lansoprazole) substantially reduce dasatinib absorption when used chronically; avoid if possible or separate timing dramatically (PPI in morning, dasatinib 12 hours later). H2 blockers (famotidine, ranitidine) similarly reduce absorption but effect can be managed with timing (dasatinib 2 hours before or 10 hours after H2 blocker). Antacids should be separated by 2 hours. Senolytic Dosing Paradigm: Intermittent dosing (e.g., 100 mg/day × 2-3 days, then drug-free for weeks to months) differs fundamentally from chronic oncologic dosing. Rationale: (1) Senolysis occurs on a short timescale (senescent cells begin dying within hours of exposure); (2) Senescent cells take weeks-to-months to regenerate after pulsed depletion; (3) Continuous dosing would expose non-senescent cells to unnecessary kinase inhibition with accumulated toxicity; (4) Intermittent pulsed dosing preserves efficacy while reducing cumulative exposure. The "hit-and-run" concept is a defining paradigm of modern senolytic research. Tissue Distribution: Dasatinib distributes broadly including into most peripheral tissues; CNS penetration is limited (dasatinib has active P-gp efflux) — a disadvantage for CNS senolytic applications where alternatives with better brain penetration may be preferred. Species Differences: Mouse and human senolytic dosing differ substantially. Mouse preclinical D+Q protocols typically use 5 mg/kg dasatinib + 50 mg/kg quercetin by oral gavage, corresponding to roughly 100 mg dasatinib + 1000 mg quercetin in humans by allometric scaling (though exact translation varies). Human pilot trials have used these dose equivalents. Emerging Senolytic Alternatives: Beyond dasatinib, other senolytic drugs are under investigation including navitoclax (ABT-263, broader BCL-2 family inhibitor with worse safety), UBX1325 (ophthalmology-focused), fisetin (natural senolytic with much better safety profile — emerging as preferred senolytic for many applications), piperlongumine, cardiac glycosides (digoxin, ouabain), and novel selective agents under clinical development. Biomarker Response: Direct measurement of senescence burden remains challenging clinically. Surrogate markers include: adipose tissue senescence (biopsy; measured in Hickson 2019); circulating inflammatory markers (hs-CRP, IL-6); senescence-associated markers (p16INK4a expression in specific tissues); functional markers (6-minute walk, physical function scores, cognitive testing).
Overview
Dasatinib (SPRYCEL) is a second-generation oral tyrosine kinase inhibitor (TKI) with FDA approvals for chronic myeloid leukemia (CML) and Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL). It is also, critically for longevity medicine, the "D" component of the landmark D+Q (dasatinib + quercetin) senolytic drug combination first reported by Zhu, Tchkonia, and Kirkland in 2015 (PMID 25754370) — the first demonstrated pharmacologic strategy to selectively kill senescent cells ("zombie cells") while sparing healthy cells. Senescent cells accumulate with age and disease, secrete pro-inflammatory and tissue-damaging SASP (senescence-associated secretory phenotype) factors, and contribute to age-related dysfunction across multiple organs. The D+Q combination and subsequent senolytic discoveries have opened an entire new therapeutic category of geroscience interventions with two landmark first-in-human pilot trials completed (Justice 2019 PMID 30616998 in idiopathic pulmonary fibrosis; Hickson 2019 PMID 31542391 in diabetic kidney disease), numerous additional senolytic trials underway, and substantial preclinical evidence across aging, Alzheimer disease, osteoarthritis, atherosclerosis, obesity-associated metabolic dysfunction, frailty, and multiple other age-related conditions. Dasatinib's chemical structure is a pyrimidinyl-aminothiazole-carboxamide that functions as an ATP-competitive inhibitor of multiple tyrosine kinases, with particular potency against BCR-ABL, the SRC family kinases (SRC, LCK, YES, FYN), c-KIT, PDGFR-α/β, and ephrin receptors. Originally developed by Bristol-Myers Squibb as a second-generation BCR-ABL inhibitor for patients with imatinib-resistant or -intolerant CML, dasatinib is 325-fold more potent than imatinib against wild-type BCR-ABL and retains activity against most imatinib-resistant mutations except T315I (which requires ponatinib). FDA-approved for: CML in all phases (chronic, accelerated, blast); Ph+ ALL in adults and pediatrics; use in adult patients with chronic phase CML with resistance or intolerance to prior therapy (second-line) or newly-diagnosed chronic phase CML (first-line); pediatric CML in chronic phase. The compound is marketed by Bristol-Myers Squibb (BMS) as SPRYCEL with substantial global presence since 2006. Dosing for oncologic indications ranges from 100 mg once daily (standard for chronic-phase CML) to 140 mg daily or 70 mg BID (for advanced CML or Ph+ ALL), taken continuously until disease progression or unacceptable toxicity. This pharmacologic profile — daily oral administration with continuous dosing at 100-140 mg — is the high-exposure scenario from which extensive clinical safety data and drug interaction knowledge have been accumulated. The senolytic paradigm is fundamentally different. For senolytic applications, dasatinib is used in INTERMITTENT PULSED DOSING — typically 100 mg once daily for 2-3 consecutive days, followed by a long drug-free interval (weeks to months). This dosing strategy reflects the biology: senolytic effects occur through a "hit-and-run" mechanism where the drug kills vulnerable senescent cells within hours to days, and continuous daily exposure is both unnecessary and likely counterproductive. The Justice 2019 trial used dasatinib 100 mg + quercetin 1000 mg on 3 consecutive days, with follow-up at 1 week and 1 month, finding meaningful functional improvements in IPF patients. The Hickson 2019 trial used dasatinib 100 mg + quercetin 1000 mg on 3 consecutive days, with measured senescent cell reduction in adipose tissue at 11 days post-treatment. Subsequent trials are exploring varied intermittent dosing schedules (e.g., monthly or quarterly pulsed dosing). This intermittent paradigm dramatically reduces cumulative exposure compared to chronic oncologic dosing — a patient receiving 100 mg × 2 days monthly gets ~2400 mg annually, compared to ~36,500 mg annually for a chronic CML patient — with correspondingly reduced but not eliminated side effect risk. Dasatinib's side effect profile is substantial and requires careful consideration even for intermittent senolytic use. Myelosuppression (thrombocytopenia, neutropenia, anemia) is common and dose-related, with thrombocytopenia being particularly notable — dasatinib potently inhibits SRC-family kinases in platelets, producing both quantitative reduction in platelet number and qualitative impairment of platelet function (increased bleeding risk independent of count). Pleural effusion is a well-described class effect (more common with dasatinib than other BCR-ABL TKIs), occurring in 10-30% of chronic daily-dosed patients and requiring monitoring. QTc prolongation and rare cardiac arrhythmias have been reported. Pulmonary arterial hypertension (rare but serious) can occur with prolonged exposure. GI side effects (diarrhea, nausea) are common. Multiple reports exist of dasatinib-induced colitis and GI bleeding. Drug interactions are extensive (CYP3A4 substrate; strong CYP3A4 inhibitors substantially increase dasatinib exposure; proton pump inhibitors dramatically reduce dasatinib absorption by raising gastric pH). For senolytic applications, intermittent pulsed dosing reduces but does not eliminate these concerns — patients have experienced adverse events at senolytic dosing schedules, and the intermittent paradigm is not risk-free. Dasatinib is a prescription medication; its use for any indication requires physician prescription, monitoring, and supervision. For longevity/senolytic use specifically, this requires partnership with a physician familiar with geroscience — typically a functional medicine, integrative medicine, or specifically-trained longevity physician. Self-experimentation with research-chemical-sourced dasatinib is both illegal (in most jurisdictions) and medically inappropriate given the substantial side effect profile and need for baseline and monitoring labs (CBC, LFTs, ECG, periodic echo for pulmonary pressure assessment). This entry covers dasatinib's pharmacology as a tyrosine kinase inhibitor; its established oncology indications; the senolytic mechanism and D+Q rationale; the clinical evidence base for senolytic applications including Justice 2019 IPF trial and Hickson 2019 DKD trial; the intermittent dosing paradigm for senolytic use; the substantial safety and interaction considerations; integration with fisetin, quercetin, rapamycin, and other geroscience interventions; and the essential role of physician partnership in any senolytic use.
Chemical Information
IUPAC Name
Not yet available
CAS Number
Not yet available
Molecular Formula
Not yet available
Molecular Mass
Not yet available
Chemical data is being compiled for this compound.
Dosing & Protocols
Unlock Dosing Protocols
Free account gets you:
- View beginner, intermediate & advanced protocols
- See weight-based dosing calculations
- Access cycle length & frequency data
2,800+ researchers already in
Research
Unlock Research Data
Free account gets you:
- Browse PubMed study summaries
- See clinical trial phases & results
- Access mechanism of action details
2,800+ researchers already in
Interactions
Contraindications
Dasatinib has significant contraindications and extensive drug interactions that substantially limit appropriate use. Absolute Contraindications: Known hypersensitivity to dasatinib or tablet excipients (rare); Active severe bleeding or coagulopathy; Severe uncontrolled cardiac arrhythmia (particularly QTc-prolonging conditions); Active severe infection (relative — may proceed after resolution); Pregnancy (Category D; contraception required during use); Breastfeeding. Strong Relative Contraindications (Essentially Exclude Use Without Specialist Guidance): Active bleeding disorder (hemophilia, severe thrombocytopenia, significant platelet dysfunction); Recent major bleeding event (GI bleed, intracranial hemorrhage, etc.); Uncontrolled cardiovascular disease (recent MI, unstable angina, severe heart failure); Pre-existing pulmonary arterial hypertension; Severe hepatic impairment (Child-Pugh C); Severe chronic kidney disease on dialysis (data limited); Active hepatitis B infection (risk of reactivation); Long QT syndrome or significant baseline QTc prolongation; History of severe dasatinib-associated adverse events; Severe platelet dysfunction from other causes (uremia, severe liver disease, etc.). Relative Contraindications (Use With Caution and Specific Precautions): Controlled bleeding risk (on antiplatelet/anticoagulants — requires bleeding risk discussion and possibly temporary holding); Mild-moderate cardiovascular disease; Mild-moderate pulmonary disease; History of pleural effusion (regardless of cause); History of GI bleeding or peptic ulcer; Chronic PPI use (impaired absorption); Multiple medications with significant drug interactions; Elderly (>75) with multiple comorbidities; Pregnancy planning (stop before conception attempts); Active cancer not related to dasatinib indication (complex interaction potential with other cancer treatments); Elective surgery planned within 2-3 weeks. Drug Interactions — COMPREHENSIVE LIST: Strong CYP3A4 Inhibitors (AVOID OR DOSE REDUCE): Antifungals: ketoconazole, itraconazole, posaconazole, voriconazole. Macrolide antibiotics: clarithromycin, telithromycin, erythromycin. HIV/HCV antivirals: ritonavir, cobicistat, lopinavir, nelfinavir, indinavir, saquinavir; elbasvir, grazoprevir (some combinations). Other: nefazodone, conivaptan; grapefruit juice regular consumption (>1 glass/day); Seville orange; pomelo; star fruit. If strong CYP3A4 inhibitor cannot be held, reduce dasatinib to 20-40 mg equivalent or use alternative senolytic. Moderate CYP3A4 Inhibitors (CAUTION/DOSE ADJUSTMENT): Calcium channel blockers: diltiazem, verapamil. Antifungals: fluconazole (mild-moderate), isavuconazole. Antibiotics: some quinolones (ciprofloxacin mild). Antiemetics: aprepitant (chemotherapy antiemetic; moderate inhibitor). Statins (as CYP3A4 inhibitors rather than substrates): atorvastatin (mild), lovastatin (mild-moderate). Hormone replacement: some progesterones. CBD: high-dose cannabidiol is moderate CYP3A4 inhibitor; clinically relevant at medical-grade doses. Strong CYP3A4 Inducers (AVOID): Antimicrobials: rifampin, rifabutin, rifapentine. Anticonvulsants: phenytoin, carbamazepine, phenobarbital, primidone, oxcarbazepine (moderate). Antiviral: efavirenz, etravirine, nevirapine. Tuberculosis treatment: isoniazid/rifampin combinations. Herbal: St. John's Wort. Other: enzalutamide, apalutamide, modafinil (moderate). If strong CYP3A4 inducer cannot be held, efficacy will be substantially reduced; consider alternative senolytic (fisetin). Gastric pH Modifiers (CRITICAL ABSORPTION INTERACTION): PPIs (ALL): omeprazole, esomeprazole, pantoprazole, lansoprazole, rabeprazole, dexlansoprazole. Chronic PPI dramatically reduces dasatinib absorption (possibly >40% reduction). Strategy: hold PPI during pulse days; if cannot hold (severe reflux, active ulcer), use H2 blocker alternative with timing separation, or use alternative senolytic (fisetin). H2 Blockers: famotidine, cimetidine, ranitidine, nizatidine. Moderate absorption effect. Strategy: dasatinib 2-10 hours before H2 blocker. Antacids: calcium carbonate, magnesium hydroxide, aluminum hydroxide, sodium bicarbonate. Moderate effect. Strategy: separate by 2 hours. Sucralfate: can affect absorption; separate by 2 hours. Bile acid sequestrants (cholestyramine, colestipol): separate by 4 hours. QTc-Prolonging Agents: Class Ia/Ic antiarrhythmics: quinidine, procainamide, disopyramide, flecainide, propafenone — additive QTc risk. Class III antiarrhythmics: amiodarone, sotalol, dofetilide, dronedarone, ibutilide — additive QTc risk plus amiodarone CYP3A4 inhibition. Antipsychotics: haloperidol, ziprasidone, quetiapine (modest), thioridazine, pimozide. Antidepressants: tricyclics (amitriptyline, imipramine, etc.), citalopram (moderate QTc effect), escitalopram. Macrolides (many — already listed as CYP3A4 inhibitors): also additive QTc. Fluoroquinolones: levofloxacin, moxifloxacin (more QTc), ciprofloxacin (less). Antiemetics: ondansetron, granisetron (mild). Others: methadone, pentamidine, some TCAs. Strategy: review ECG baseline; avoid combinations in patients with baseline QTc prolongation. Anticoagulants: Warfarin: additive bleeding risk; INR monitoring during dasatinib exposure; possible dose adjustment. DOACs: apixaban, rivaroxaban, dabigatran, edoxaban — additive bleeding risk; consider holding during pulse days if clinical situation allows. Heparins/LMWH: enoxaparin, dalteparin, fondaparinux, heparin — additive bleeding risk; avoid overlap when possible. Antiplatelet Agents: Aspirin (all doses including low-dose cardiovascular prophylaxis) — additive antiplatelet effect; bleeding risk consideration; some protocols hold 81 mg aspirin during pulse days. P2Y12 inhibitors: clopidogrel, prasugrel, ticagrelor — significant additive antiplatelet effect; bleeding risk; some protocols hold during pulse days. Dipyridamole, cilostazol — additive antiplatelet. NSAIDs: All NSAIDs (ibuprofen, naproxen, diclofenac, meloxicam, celecoxib, ketorolac, etc.) — additive bleeding and GI effects; hold during pulse days and avoid for at least 3 days post-pulse when possible. Acetaminophen acceptable as NSAID alternative. Other Kinase Inhibitors: Combination with other TKIs (imatinib, nilotinib, bosutinib, ponatinib, sunitinib, sorafenib, etc.) is generally avoided in senolytic contexts; may be relevant in complex oncology cases. Immunosuppressants: tacrolimus, cyclosporine, sirolimus, everolimus — CYP3A4 interactions; monitor drug levels; avoid combinations when possible. Hormone Replacement: estrogens, progestins — generally compatible; some modest CYP3A4 interactions. Contraceptives: oral contraceptives generally compatible; injectable contraceptives no interaction. Pregnancy Prevention: women of reproductive potential on dasatinib must use reliable contraception during treatment. Antidiabetic Agents: insulin, sulfonylureas, metformin, GLP-1 agonists, SGLT2 inhibitors — generally compatible; monitor glucose. Thyroid Hormone (Levothyroxine): generally compatible; some reports of thyroid dysfunction with dasatinib (monitor TFTs periodically). Psychiatric Medications: SSRIs, SNRIs — mild QTc considerations (particularly citalopram, escitalopram); additive bleeding risk with SSRIs; generally usable with monitoring. Pain Management: Opioids — generally compatible; fentanyl and some others CYP3A4 metabolized so exposure may be affected. Inhaled Medications: inhaled corticosteroids, bronchodilators — no significant interaction. Topical Medications: no significant systemic interactions. Herbal Interactions: St. John's Wort (CYP3A4 inducer) — avoid. Goldenseal (CYP3A4 inhibitor) — caution. Kava — avoid (hepatotoxicity). Ginkgo — additive bleeding. Garlic (high-dose) — additive bleeding. Ginger (high-dose) — additive bleeding. Ginseng — modest CYP3A4 effects; generally compatible. Milk thistle — generally compatible. Turmeric/Curcumin — compatible at typical supplemental doses; additive antiplatelet at high doses. Green tea extract (high dose) — potential CYP3A4 effects. Alcohol: Avoid during and for 24 hours after pulse days. Moderate consumption between cycles acceptable. Heavy drinking should be addressed regardless of dasatinib use. Tobacco: Not a direct pharmacokinetic interaction but smokers have increased cardiovascular and pulmonary risk that compounds dasatinib risks. Cannabis: High-dose CBD is CYP3A4 inhibitor (relevant); THC has less interaction but may have cardiac effects at high dose. Generally minimize during pulse days. Food: Grapefruit juice (avoid during pulse). Regular balanced meals acceptable. Take with or without food. Laboratory Test Effects: Dasatinib does not typically interfere with common laboratory assays. May affect thyroid function tests modestly with chronic use. Surgical Considerations: Hold dasatinib at least 1 week before elective surgery; longer (2-3 weeks) if possible given platelet function effects. Emergency surgery: consider platelet transfusion for significant bleeding; discuss with hematology for management. Dental Procedures: Hold dasatinib at least 1 week before invasive dental procedures (extractions, implants, deep cleaning with significant bleeding); routine cleaning without bleeding generally acceptable. Vaccinations: Live vaccines generally avoided during oncologic TKI therapy; intermittent senolytic dosing may be more permissive but timing considerations important (e.g., receive vaccines at least 2 weeks before or 2 weeks after pulse). Inactivated vaccines generally acceptable. Special Populations: Elderly (>65): Compatible with monitoring; higher comorbidity burden requires careful drug interaction review; dose reduction may be appropriate. Frail elderly (>80): Consider alternative senolytics (fisetin) given better safety profile. Renal Impairment: No specific dose adjustment for mild-moderate; limited data severe. Hepatic Impairment: Dose reduction for moderate; avoid for severe. Pregnancy: Contraindicated. Breastfeeding: Contraindicated. Pediatric Senolytic Use: NOT appropriate outside specific trials. Active Cancer: Oncologic coordination essential. Transplant Recipients: Immunosuppressant interactions; specialist coordination. HIV/HCV Patients: Antiretroviral interactions; specialist coordination. Regulatory Status: Prescription-only globally. Off-label senolytic use requires licensed physician prescription. Quality/Product: Use only pharmacy-sourced product with prescription; avoid research-chemical sources. Overdose: Rare in senolytic context given intermittent dosing. Management: supportive care; monitor for cytopenias, bleeding, fluid retention, cardiac symptoms; no specific antidote. Discontinuation: Can be stopped abruptly without withdrawal. Senescent cell burden gradually increases post-discontinuation. Symptoms Requiring Urgent Medical Attention: GI bleeding (melena, hematemesis, hematochezia); severe fatigue with pallor; shortness of breath; chest pain; severe headache with neurologic symptoms; prolonged/heavy bleeding; severe abdominal pain; edema with weight gain; jaundice; severe rash with systemic symptoms; fever suggesting infection. Final Assessment: Dasatinib has one of the most extensive drug interaction and safety consideration profiles of any intervention commonly used in longevity medicine. Appropriate use requires complete clinical partnership. For many patients, fisetin provides a substantially safer senolytic option that can be used OTC without the interaction complexity.
Research Disclaimer
This interaction data is compiled from published research and community reports. It may not be exhaustive. Always consult a healthcare professional before combining compounds.
No listings found for Dasatinib.
Research Score
0 PubMed studies
Quality Indicators
Data Completeness
50%Quick Facts
Trial Phase
Preclinical
Research Disclaimer
This information is for educational and research purposes only. Not intended as medical advice. Consult a healthcare professional before use.
Frequently Asked Questions
What is the D+Q senolytic combination?
D+Q is the combination of Dasatinib + Quercetin, the first drug combination demonstrated to selectively kill senescent cells (senolytic activity), established in the landmark paper by Zhu, Tchkonia, and Kirkland (2015, PMID 25754370). Dasatinib is a prescription tyrosine kinase inhibitor (SPRYCEL, originally for CML) that targets SRC family kinases and ephrin receptors in senescent cells. Quercetin is an OTC flavonoid that targets PI3K/AKT, BCL-XL, and HIF-1α pathways in senescent cells. The two compounds have complementary senolytic specificity — dasatinib is most effective against senescent endothelial cells and adipocyte progenitors; quercetin is most effective against senescent pre-adipocytes and mouse embryonic fibroblasts. Combined, D+Q covers a broader range of senescent cell types than either alone. Standard senolytic dosing: Dasatinib 100 mg once daily + Quercetin 1000 mg once daily for 2-3 consecutive days, then a long drug-free interval (typically monthly or quarterly). This 'hit-and-run' pulsed approach reflects the rapid timescale of senolysis and reduces cumulative toxicity vs. chronic daily dosing. Human pilot trials: Justice 2019 (PMID 30616998) in idiopathic pulmonary fibrosis showed significant physical function improvements after 3 cycles of D+Q. Hickson 2019 (PMID 31542391) in diabetic kidney disease showed measurable reduction in senescent cell markers in adipose tissue. Ongoing trials in Alzheimer disease, osteoarthritis, frailty, and other indications. Important caveat: Dasatinib requires prescription and has substantial side effects (myelosuppression, bleeding risk, pleural effusion, QTc prolongation, drug interactions). Physician partnership is essential. Many longevity practitioners now prefer fisetin-based senolytic protocols for better safety, reserving D+Q for specific higher-acuity situations.
Is dasatinib safe for longevity use?
Dasatinib has a substantial side effect profile even in intermittent senolytic dosing — it is NOT a benign intervention. Established safety concerns (documented in oncologic daily dosing but reduced in senolytic intermittent use): Myelosuppression (thrombocytopenia, neutropenia, anemia); pleural effusion (10-30% with chronic daily dosing; less common but reported with intermittent); bleeding risk from platelet dysfunction (independent of platelet count — clinically significant); pulmonary arterial hypertension (rare but serious); QTc prolongation; GI side effects including diarrhea, nausea, and notably GI bleeding (reported even in senolytic pulse dosing); hepatotoxicity (LFT elevations); fluid retention. Intermittent senolytic dosing (e.g., 100 mg × 2 days monthly) reduces cumulative exposure ~15-fold vs. chronic CML dosing, with correspondingly reduced adverse event rates, but risks are NOT eliminated. Pilot trials and off-label use have reported adverse events including bleeding episodes, severe fatigue, GI symptoms, and rarely more serious events even at senolytic doses. Who can safely use dasatinib for senolytic purposes: Appropriate candidates: Older adults (>55) with specific rationale (elevated senescence burden, targeted indication); No active bleeding disorders or significant bleeding risk; No active cardiac or pulmonary disease; Manageable drug interaction profile; Partnership with physician familiar with senolytic use; Ability to follow monitoring protocols; Informed understanding of investigational nature. Poor candidates: Young adults without specific indication; Active bleeding or coagulopathy; Severe cardiac/pulmonary disease; Multiple unmodifiable drug interactions (especially PPI dependence); Unable to establish physician partnership; Seeking 'fountain of youth' miracle. Safer alternative for most people: Fisetin 1000-2000 mg × 2-3 days monthly. OTC, minimal side effects, no prescription required, emerging evidence base. For most people interested in senolytic approaches, fisetin is the appropriate entry point. Dasatinib is reserved for specific situations where more potent intervention is warranted and the risk-benefit supports it under physician supervision.
Can I buy dasatinib over the counter or from research chemical sites?
No — and you shouldn't try. Dasatinib is a prescription medication globally; it is not available OTC. Research chemical sources that sell dasatinib without prescription should be avoided for multiple reasons: Quality concerns: Research-chemical suppliers have no quality assurance standards equivalent to pharmaceutical manufacturing. Content may be incorrect (wrong molecule, contaminated, wrong concentration). Heavy metal contamination, dissolution variability, and adulterants have been documented in similar contexts. Legal concerns: Importation of prescription medications without prescription is illegal in most jurisdictions. Personal importation for 'personal use' has limited exceptions but dasatinib generally doesn't qualify. Customs seizures occur; potential legal consequences vary. Medical concerns: Dasatinib's substantial side effect profile requires baseline evaluation (CBC, ECG, LFTs), drug interaction review, and ongoing monitoring. Use without this framework is medically inappropriate. Alternative pathway: Legitimate off-label prescription. Physicians can legally prescribe FDA-approved medications for off-label uses at their clinical discretion. Finding a physician willing to prescribe dasatinib for senolytic use: Longevity medicine specialists; Functional medicine physicians with specific senolytic experience; Research clinics running senolytic trials (possibly providing access within trial framework); Some integrative oncologists with senescence interest. Realistic cost: Generic dasatinib 100 mg is now available (2020+) at substantially reduced cost vs. brand Sprycel. Cash pay pricing through Mark Cuban Cost Plus Drugs and similar transparent pharmacies may be manageable for many users. Insurance typically does not cover off-label senolytic use. Alternative if prescription pathway not feasible: Fisetin — natural flavonoid with senolytic activity; OTC; minimal side effects; emerging evidence base. Available without prescription; reasonable cost ($30-50/month for typical cycles); much safer profile. For most people, fisetin is the appropriate pathway for senolytic interest.
How does dasatinib senolytic dosing differ from oncologic dosing?
Fundamentally different in both schedule and cumulative exposure. Oncologic dosing (FDA-approved): Chronic daily dosing — 100 mg/day (standard CML chronic phase) or up to 140 mg/day for advanced disease. Continuous indefinitely until disease progression or toxicity. Annual exposure: ~36,500 mg (100 mg × 365 days). Senolytic dosing (off-label): Intermittent pulsed dosing — 100 mg/day × 2-3 consecutive days, followed by drug-free interval of weeks to months (typically monthly to quarterly). Annual exposure: ~400-2400 mg (e.g., 200 mg × 12 monthly cycles = 2400 mg; 200 mg × 4 quarterly cycles = 800 mg). Ratio: Senolytic annual exposure is ~5-15% of oncologic annual exposure. Biological rationale for intermittent senolytic dosing: Senescent cells are killed within hours to days of exposure — prolonged daily dosing is unnecessary for senolytic effect. Senescent cells regenerate over weeks to months after depletion — short intervals between cycles are unproductive. Chronic exposure would produce continuous on-target kinase inhibition of non-senescent cells with accumulated toxicity (hematologic, pulmonary, cardiovascular). The 'hit-and-run' paradigm preserves senolytic efficacy while minimizing cumulative toxicity. Clinical implications: Safety profiles differ substantially — oncologic patients on chronic dosing have much higher rates of pleural effusion, myelosuppression, and drug-related mortality compared to senolytic intermittent users. However, senolytic dosing is NOT risk-free — pilot trials and off-label use have reported adverse events at intermittent doses. Evidence base differs: Oncologic use is FDA-approved with extensive RCT evidence. Senolytic use is off-label with limited pilot trial evidence (Justice 2019, Hickson 2019, and ongoing trials). Dose equivalence to oncologic trials: A patient receiving 100 mg × 2 days monthly for a year receives approximately 6.6% of what a CML patient receives in a year. This substantially reduced cumulative exposure underlies the expectation that senolytic dosing is safer than chronic daily use — though safety data specifically for long-term intermittent senolytic use is still accumulating. Most common senolytic schedule: 100 mg × 2 consecutive days + 1000 mg quercetin × 2 consecutive days, monthly or quarterly. Most longevity practitioners use monthly dosing during active intervention periods, transitioning to quarterly maintenance.
What's the difference between dasatinib and fisetin for senolytic purposes?
Both target senescent cells but through different mechanisms, with substantially different safety profiles and access considerations. Mechanism: Dasatinib inhibits SRC family kinases and ephrin receptors (pro-survival pathways in senescent cells). Fisetin is a natural flavonoid (chemically related to quercetin) that targets PI3K/AKT and BCL-XL pathways — similar but not identical to quercetin's mechanism. Evidence base: Dasatinib-based senolytic (D+Q) has the first human pilot trial data (Justice 2019 IPF; Hickson 2019 DKD) with measured functional and biomarker improvements. Fisetin has strong preclinical evidence and some ongoing clinical trials but less published human outcome data than D+Q. Both are investigational for senolytic use. Potency: Dasatinib is more potent per milligram (100 mg produces meaningful senolytic effect). Fisetin requires higher absolute doses (1000-2000 mg/day for senolytic effect) to achieve comparable clinical activity, but higher doses are tolerable given fisetin's much better safety profile. Safety: Dasatinib has substantial side effect profile — myelosuppression, bleeding risk, pleural effusion, QTc prolongation, extensive drug interactions. Even intermittent senolytic dosing carries risk. Fisetin has minimal side effects at senolytic doses — mild GI effects occasionally, no myelosuppression, no significant bleeding concerns, minimal drug interactions. Massively safer profile. Access: Dasatinib is prescription-only; requires physician partnership familiar with senolytic use; generic now available but still requires legitimate medical pathway. Fisetin is OTC supplement; widely available; reasonable cost ($30-50/month for typical cycles); no prescription needed. Cost: Dasatinib: variable; generic dasatinib ~$50-200/month for typical senolytic cycling; brand Sprycel substantially more. Fisetin: ~$30-50/month for 1000-2000 mg/day cycles. Practical recommendation for most people interested in senolytic approaches: Start with fisetin 1000-2000 mg × 2-3 consecutive days monthly. Track response over 6-12 cycles. If inadequate response or specific high-acuity indication, discuss dasatinib-based protocol with longevity medicine physician. When dasatinib may be preferred: Specific disease indications with strong senescent cell contribution (IPF, severe OA, metabolic dysfunction with significant senescence markers); Patient with adequate resources for physician partnership and monitoring; Patient without significant contraindications to dasatinib; Patient who has not responded to fisetin-based approach. Combined approach: Some protocols rotate D+Q and fisetin cycles to diversify senolytic coverage.
Can dasatinib reverse aging?
No — dasatinib is not an 'anti-aging' drug that reverses aging. More accurately, dasatinib (as part of D+Q senolytic combination) reduces senescent cell burden, which may improve some age-related dysfunction. The distinction matters for realistic expectations. What senolytics demonstrably do: Kill some senescent cells in preclinical models and humans (Hickson 2019 showed reduced p16INK4a positive cells in adipose tissue after D+Q); Reduce some inflammatory SASP factors in biomarker studies; Improve physical function measures in specific populations (IPF patients in Justice 2019 showed improved 6-minute walk; preclinical frailty models show function improvements); Extend lifespan in specific mouse models (Xu 2018 showed 36% lifespan extension in late-life treated mice). What senolytics do NOT demonstrably do: Reverse fundamental aging processes (telomere shortening, stem cell exhaustion, epigenetic drift, protein homeostasis decline — most of these are not directly addressed by senolytics); Make an 80-year-old function like a 30-year-old; Prevent all age-related disease (senescence is one of ~12 hallmarks of aging; addressing one hallmark doesn't address all); Replace comprehensive healthy aging strategy (lifestyle, preventive medicine, targeted disease management). Realistic framework: Senolytics are one potential tool in multi-factorial healthspan management. They may improve some aspects of aging-related dysfunction in specific contexts; they are not a fountain of youth. Evidence limitations: Human clinical trials are small, short-term, and focused on specific indications. Large-scale RCT evidence for general longevity benefit is lacking. Long-term effects (cancer rates, cardiovascular outcomes, all-cause mortality) require much larger and longer studies than have been completed. What matters more for healthspan/lifespan: Lifestyle foundation (exercise, nutrition, sleep, stress management, social engagement, cognitive engagement, avoidance of smoking/excess alcohol) — evidence for these interventions substantially exceeds evidence for any pharmacologic senolytic. Preventive medical care (cancer screening, cardiovascular risk management, routine care). Treatment of established disease (diabetes, hypertension, depression, etc.). Senolytics in context: Reasonable addition to comprehensive longevity strategy for appropriate candidates under physician supervision. Not a replacement for fundamentals. Not a miracle intervention. Realistic expectations lead to better outcomes and more sustainable use.
Do I need special labs before starting dasatinib?
Yes — baseline and ongoing monitoring are essential for safe dasatinib use, even for intermittent senolytic dosing. Baseline Labs (before any dasatinib exposure): Complete Blood Count (CBC) with differential and platelets — establishes baseline for monitoring myelosuppression. Counts should be within normal range before first pulse. Comprehensive Metabolic Panel (CMP) — includes creatinine (renal function), electrolytes, liver enzymes (ALT, AST, alkaline phosphatase, bilirubin), glucose. Baseline liver function particularly important. Coagulation Studies (PT/INR, aPTT) — baseline for patients on anticoagulants or with bleeding history. ECG (12-lead) — baseline QTc interval and assessment for any existing cardiac abnormalities. QTc >470 ms relative contraindication; >500 ms absolute. Echocardiogram — baseline pulmonary pressure assessment, left ventricular function. Particularly important if long-term use anticipated. Hepatitis B Screening — HBsAg, anti-HBc (total or IgG), anti-HBs. HBV reactivation has been reported with dasatinib. Active HBV or past infection requires management plan. HIV Screening — if not recently performed; relevant given antiretroviral drug interactions. Thyroid Function — TSH baseline; dasatinib has been associated with thyroid dysfunction. Lipid Panel — general cardiovascular risk assessment. Fasting Glucose/HbA1c — particularly if diabetic or prediabetic. Inflammatory Markers (optional but informative) — hs-CRP, IL-6 for tracking senolytic response. Senescence-specific biomarkers (research) — p16INK4a expression in PBMCs; epigenetic age clocks (DunedinPACE, GrimAge, Horvath). Emerging utility. Medication Reconciliation — comprehensive review with pharmacist for drug interactions (CYP3A4, gastric pH modifiers, bleeding risk compounds). Echocardiogram Rationale: Dasatinib has rare but serious associations with pulmonary arterial hypertension (reversible if recognized early, potentially fatal if not). Baseline echo provides reference point; periodic repeat (annually for long-term users) detects emerging issues. Ongoing Monitoring Cadence: Every pulse for first 3 cycles: CBC 7-14 days post-pulse; symptom review; tolerance assessment. Every 3 months in first year: CBC, CMP, LFTs. Every 6 months after first year: CBC, CMP, LFTs, thyroid function. Annually: ECG, clinical review, risk-benefit reassessment. Biennially: echocardiogram for long-term users. Symptom Monitoring Between Labs: Daily awareness of: unusual bleeding or bruising; fatigue beyond expected transient post-pulse fatigue; shortness of breath; chest pain; GI symptoms; persistent headache; weight gain/edema; rashes. Any significant symptom triggers immediate labs and physician contact. Cost Considerations: Baseline evaluation typical cost $500-1500 depending on insurance coverage and test selection. Ongoing monitoring typically <$500 annually in most insurance scenarios. If labs show abnormalities: Address underlying cause (may preclude dasatinib use); Modify protocol (dose reduction, schedule extension); Consider alternative senolytic (fisetin avoids most of these monitoring requirements). For fisetin-based senolytic (alternative): Much simpler monitoring requirements — basic CBC and CMP sufficient for most users; no ECG or echo required. This is one of the reasons fisetin is preferred for many candidates.
How often should I take dasatinib for senolytic purposes?
Typical schedules are monthly to quarterly, not daily. The optimal frequency is not definitively established. Common schedules (dasatinib 100 mg + quercetin 1000 mg per pulse day): Monthly pulsing: D+Q for 2 consecutive days each month (~24 treatment days per year). Most aggressive common schedule. Used in: high senescent cell burden contexts, active disease management phases, early intervention periods. Every 6-8 weeks: D+Q for 2 consecutive days every 6-8 weeks (~12-18 treatment days per year). Moderate schedule. Used for: general healthspan maintenance, transition from more intensive schedule. Quarterly (every 3 months): D+Q for 2-3 consecutive days every 3 months (~8-12 treatment days per year). Conservative maintenance. Used for: long-term maintenance, older/frail patients, cumulative toxicity minimization. Biomarker-driven: Treatment when inflammatory markers rise above threshold — typically monthly hs-CRP monitoring with treatment triggered at significant elevation. Research protocol-based: Specific schedules from published trials (e.g., Justice 2019 used D+Q daily × 3 consecutive days per week × 3 weeks — a very intensive protocol for specific IPF indication). Factors influencing frequency choice: Patient age and frailty (frailer patients → less frequent); Senescent cell burden (higher burden → more frequent initially); Specific indication (targeted disease → trial-guided schedule); Response to treatment (good response → maintenance schedule; partial response → consider more frequent); Tolerance (adverse events → less frequent); Cost constraints; Physician preference/experience. Duration considerations: Some practitioners use finite courses (12-24 cycles over 1-2 years) then discontinue; others maintain indefinitely. Evidence basis for either approach is limited. Rationale for NOT dosing more frequently than monthly: Senescent cells require weeks-to-months to regenerate after depletion; more frequent dosing provides unnecessary additional exposure without proportional senolytic benefit. Cumulative dasatinib toxicity (myelosuppression, pleural effusion risk) accumulates with frequency. Rationale for NOT dosing less frequently than quarterly: Senescent cell burden gradually re-accumulates; too-infrequent dosing may not maintain clinical benefit. Individual experimentation within safe bounds: Some individuals may respond to less frequent dosing (every 6 months) while others may need more frequent (monthly). Individual response variation is significant. Tracking outcomes across cycles informs personalization. Context within comprehensive protocol: Frequency of dasatinib pulsing matters less than overall quality of longevity protocol including lifestyle foundation, chronic daily components, appropriate medical care, and realistic expectations. Most of the benefit comes from the comprehensive approach, not from optimizing dasatinib frequency.
Can dasatinib cause cancer or increase cancer risk?
This is a theoretical concern but the evidence picture is complex — current clinical evidence does not demonstrate increased cancer risk from intermittent senolytic dasatinib dosing. Theoretical Concern Rationale: Senescence is a tumor-suppressor mechanism — cells that become senescent stop dividing and therefore cannot become cancerous. If senolytics remove these senescent cells prematurely, theoretically cells that 'should' have become senescent (as protection against cancer) might instead continue replicating with damaged DNA, potentially increasing cancer risk. Counter-argument: Chronic senescence burden contributes to tumor-permissive microenvironment through SASP factors that promote tumor growth, invasion, and angiogenesis. Appropriately timed senolytic intervention may actually REDUCE cancer risk by removing senescent cells that support tumor progression. Mouse cancer models have generally shown senolytic benefit (reduced tumor growth, improved response to chemotherapy). Current Human Evidence: Limited. Short-term pilot trials (Justice 2019, Hickson 2019) have not reported cancer signals but were too small and short to detect such effects. Long-term cancer risk of intermittent D+Q in humans is NOT definitively characterized. Oncologic Dasatinib Safety Data: Chronic dasatinib use in CML patients (daily for years) has extensive safety data. Cancer incidence in this population is complicated by their underlying leukemia and other factors, but dasatinib itself has not been associated with increased non-leukemia cancer risk. This provides some reassurance about the parent compound's carcinogenicity, though intermittent senolytic dosing is different exposure pattern. Preclinical Models: Mouse studies of chronic D+Q (Xu 2018 and others) have shown lifespan extension without increased cancer mortality — suggesting net-positive effects in those models. Context for risk assessment: Aging itself dramatically increases cancer risk (majority of cancers occur in older adults). Any intervention affecting aging processes necessarily interacts with cancer biology. Lifestyle factors (smoking, alcohol, obesity, sedentary behavior, diet) have much larger cancer risk effects than any senolytic intervention. Specific situations where cancer risk concern is elevated: Active cancer or recent cancer treatment — coordinate with oncology; senolytics may have specific role in cancer treatment adjunct but requires oncologic supervision. Strong family history of cancer, particularly rare hereditary cancer syndromes — discuss with genetic counselor and oncology. Known precancerous conditions. Younger patients (<40) with no specific rationale for senolytic use — cancer risk concerns combined with lower senescence burden and less evidence basis. Practical approach: For appropriate senolytic candidates (older adults, specific indications, physician-supervised), cancer risk appears acceptable based on current evidence. Ongoing surveillance (routine cancer screening per guidelines) remains important. Long-term follow-up studies will clarify cancer risk/benefit over 5-20 year time horizons. If patient has cancer history: Involve oncology in senolytic decision-making. Some evidence suggests senolytics may improve outcomes during/after cancer treatment by clearing treatment-induced senescence. Other contexts may warrant caution. Individualized decision. Bottom line: Theoretical cancer risk exists but is not supported by current clinical evidence as a significant concern at intermittent senolytic dosing. Appropriate vigilance with routine cancer screening and thoughtful patient selection is reasonable approach. Long-term definitive data will accumulate over the coming decade.
What should I do if I experience bleeding after a D+Q pulse?
Bleeding events after dasatinib exposure require prompt evaluation. The approach depends on severity. Minor bleeding (common, usually manageable): Easy bruising with minimal trauma; minor nosebleeds resolving spontaneously; slight bleeding from gums with brushing; small amount of blood in stool from known hemorrhoids. Actions: Monitor; apply pressure for external bleeding; avoid NSAIDs, aspirin, and other antiplatelet agents; stay well-hydrated; report to physician at next routine contact. Moderate bleeding (requires physician notification): Significant nosebleeds requiring intervention to stop; bleeding gums with significant blood; bruising that is progressive or spontaneous without trauma; microscopic or visible hematuria; melena or hematochezia without clear cause; menorrhagia significantly heavier than usual. Actions: Contact physician within 24 hours; discontinue all antiplatelet/anticoagulant agents until evaluated; obtain CBC to assess platelet count; avoid further dasatinib exposure pending evaluation; consider holding or discontinuing scheduled next pulse until cleared. Severe bleeding (EMERGENCY): Hematemesis (vomiting blood); significant GI bleeding with hemodynamic effects (dizziness, weakness); intracranial bleeding symptoms (severe headache with neurologic symptoms, visual changes, weakness, altered mental status); significant spontaneous bruising with hemodynamic effects; uncontrolled bleeding from any site. Actions: GO TO EMERGENCY ROOM IMMEDIATELY. Inform ER providers of recent dasatinib exposure. Provide medication list. Expect CBC, coagulation studies, possible imaging. Potential interventions: platelet transfusion for significant thrombocytopenia; transfusions for blood loss; endoscopy for GI source; neuroimaging for suspected intracranial; surgical intervention if needed. Post-Bleeding Management: Permanently discontinue dasatinib pending comprehensive evaluation; Review what contributed to bleeding (platelet function, drug interactions, underlying condition); Recover fully before considering any resumption; Most bleeding events warrant permanent discontinuation of dasatinib — not worth the ongoing risk. For Future Senolytic Interest After Bleeding Event: Strongly consider fisetin as alternative — much better bleeding safety profile. Some patients who have had bleeding on dasatinib can use fisetin safely. Prevention Strategies During Pulse Days: Review and hold antiplatelet agents (aspirin, clopidogrel, ticagrelor) during pulse days per physician guidance; Avoid NSAIDs during and 3 days post-pulse; Hold ginkgo, high-dose garlic, high-dose fish oil during pulse days; Avoid alcohol during pulse days; Avoid strenuous new exercise during pulse days (risk of unexpected injury/bruising); Avoid dental procedures within 1-2 weeks of pulse; Avoid invasive procedures within 1-2 weeks of pulse. Individuals with higher baseline bleeding risk should avoid dasatinib entirely: Hereditary bleeding disorders (hemophilia, von Willebrand disease); Chronic anticoagulation (unless temporarily holdable); Prior major bleeding events on TKIs or similar agents; Significant platelet dysfunction from other causes; GI bleeding history (especially recent or recurrent); Intracranial hemorrhage history. For these patients, fisetin-based senolytic approach is much more appropriate.
Research Tools
Free 2026 Peptide Cheat Sheet — 50 pages, PDF
Dosing, reconstitution, stacks, half-lives, and vendor trust tiers. The reference we wish we had on day one.
